Combined brachytherapy with external beam radiotherapy for localized prostate cancer: Reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy

摘要: Abstract Purpose To report the acute and late treatment-related toxicities of combined permanent interstitial 125I implantation delivered via real-time intraoperative planning supplemental intensity-modulated radiotherapy (IMRT) for patients with clinically localized prostate cancer. Methods materials One hundred twenty-seven were treated a modality (CM) regimen consisting (110 Gy) using transrectal ultrasound-guided approach followed 2 months later by 50.4 Gy IMRT directed to seminal vesicles. Late toxicity was scored according NCI Common Terminology Criteria Adverse Events scale. The compared contemporaneously cohort 216 alone prescribed dose 144 Gy. Results incidence Grade rectal urinary side effects 1% 10%, respectively, developed 3 toxicities. 4-year gastrointestinal 9%, no or 4 complications have been observed. gastrourinary 15% 1 patient urethral stricture, which corrected dilatation. percentage who experienced resolution symptoms 92% 65%, respectively. Multivariate analysis revealed that in addition higher baseline International Prostate Symptom Score, those implant CM more likely experience symptoms. Increased noted (9% vs. 1%; p = 0.001) as well significant increase (15% 9%; p = 0.004). Conclusions Adherence constraints combination brachytherapy is associated low Acute signficantly less common alone.